Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study.

Anderson KE, Eberly S, Marder KS, Oakes D, Kayson E, Young A, Shoulson I; PHAROS Investigators.

Clin Genet. 2019 May 15. doi: 10.1111/cge.13529. [Epub ahead of print]

PMID:
31093973
2.

SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson's disease.

Alcalay RN, Mallett V, Vanderperre B, Tavassoly O, Dauvilliers Y, Wu RYJ, Ruskey JA, Leblond CS, Ambalavanan A, Laurent SB, Spiegelman D, Dionne-Laporte A, Liong C, Levy OA, Fahn S, Waters C, Kuo SH, Chung WK, Ford B, Marder KS, Kang UJ, Hassin-Baer S, Greenbaum L, Trempe JF, Wolf P, Oliva P, Zhang XK, Clark LN, Langlois M, Dion PA, Fon EA, Dupre N, Rouleau GA, Gan-Or Z.

Mov Disord. 2019 Apr;34(4):526-535. doi: 10.1002/mds.27642. Epub 2019 Feb 20.

PMID:
30788890
3.

Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease.

Ruskey JA, Greenbaum L, Roncière L, Alam A, Spiegelman D, Liong C, Levy OA, Waters C, Fahn S, Marder KS, Chung W, Yahalom G, Israeli-Korn S, Livneh V, Fay-Karmon T, Alcalay RN, Hassin-Baer S, Gan-Or Z.

Eur J Med Genet. 2019 Jan;62(1):65-69. doi: 10.1016/j.ejmg.2018.05.005. Epub 2018 May 26.

PMID:
29842932
4.

Progression in the LRRK2-Asssociated Parkinson Disease Population.

Saunders-Pullman R, Mirelman A, Alcalay RN, Wang C, Ortega RA, Raymond D, Mejia-Santana H, Orbe-Reilly M, Johannes BA, Thaler A, Ozelius L, Orr-Urtreger A, Marder KS, Giladi N, Bressman SB; LRRK2 Ashkenazi Jewish Consortium.

JAMA Neurol. 2018 Mar 1;75(3):312-319. doi: 10.1001/jamaneurol.2017.4019.

5.

Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers.

Vilas D, Sharp M, Gelpi E, Genís D, Marder KS, Cortes E, Vonsattel JP, Tolosa E, Alcalay RN.

Mov Disord. 2018 Feb;33(2):335-338. doi: 10.1002/mds.27225. Epub 2017 Nov 9. No abstract available.

PMID:
29119599
6.

Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.

Corriveau RA, Koroshetz WJ, Gladman JT, Jeon S, Babcock D, Bennett DA, Carmichael ST, Dickinson SL, Dickson DW, Emr M, Fillit H, Greenberg SM, Hutton ML, Knopman DS, Manly JJ, Marder KS, Moy CS, Phelps CH, Scott PA, Seeley WW, Sieber BA, Silverberg NB, Sutherland ML, Taylor A, Torborg CL, Waddy SP, Gubitz AK, Holtzman DM.

Neurology. 2017 Dec 5;89(23):2381-2391. doi: 10.1212/WNL.0000000000004717. Epub 2017 Nov 8. Review.

7.

Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis.

Chan RB, Perotte AJ, Zhou B, Liong C, Shorr EJ, Marder KS, Kang UJ, Waters CH, Levy OA, Xu Y, Shim HB, Pe'er I, Di Paolo G, Alcalay RN.

PLoS One. 2017 Feb 17;12(2):e0172348. doi: 10.1371/journal.pone.0172348. eCollection 2017.

8.

Arm swing as a potential new prodromal marker of Parkinson's disease.

Mirelman A, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, Gurevich T, Gana-Weisz M, Saunders-Pullman R, Raymond D, Doan N, Bressman SB, Marder KS, Alcalay RN, Rao AK, Berg D, Brockmann K, Aasly J, Waro BJ, Tolosa E, Vilas D, Pont-Sunyer C, Orr-Urtreger A, Hausdorff JM, Giladi N.

Mov Disord. 2016 Oct;31(10):1527-1534. doi: 10.1002/mds.26720.

9.

SCARB2 variants and glucocerebrosidase activity in Parkinson's disease.

Alcalay RN, Levy OA, Wolf P, Oliva P, Zhang XK, Waters CH, Fahn S, Kang U, Liong C, Ford B, Mazzoni P, Kuo S, Johnson A, Xiong L, Rouleau GA, Chung W, Marder KS, Gan-Or Z.

NPJ Parkinsons Dis. 2016;2. pii: 16004. Epub 2016 Mar 10.

10.

CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease.

Terrelonge M Jr, Marder KS, Weintraub D, Alcalay RN.

J Mol Neurosci. 2016 Jan;58(1):88-92. doi: 10.1007/s12031-015-0647-x. Epub 2015 Sep 2.

11.

Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.

Helmich RC, Thaler A, van Nuenen BF, Gurevich T, Mirelman A, Marder KS, Bressman S, Orr-Urtreger A, Giladi N, Bloem BR, Toni I; LRRK2 Ashkenazi Jewish Consortium.

Neurology. 2015 Jan 27;84(4):399-406. doi: 10.1212/WNL.0000000000001189. Epub 2014 Dec 24.

12.

Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, Ruiz-Martínez J, Marti-Masso JF, Ferrer I, López de Munain A, Goldman SM, Schüle B, Langston JW, Aasly JO, Giordana MT, Bonifati V, Puschmann A, Canesi M, Pezzoli G, Maues De Paula A, Hasegawa K, Duyckaerts C, Brice A, Stoessl AJ, Marras C.

JAMA Neurol. 2015 Jan;72(1):100-5. doi: 10.1001/jamaneurol.2014.2704.

13.

The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.

Sharp ME, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C, Waters C, Fahn S, Cote L, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Payami H, Molho E, Factor SA, Nutt J, Serrano C, Arroyo M, Pauciulo MW, Nichols WC, Clark LN, Alcalay RN, Marder KS.

Mov Disord. 2015 Feb;30(2):278-83. doi: 10.1002/mds.26065. Epub 2014 Nov 12.

14.

Variability in interval production is due to timing-dependent deficits in Huntington's disease.

Rao AK, Marder KS, Uddin J, Rakitin BC.

Mov Disord. 2014 Oct;29(12):1516-22. doi: 10.1002/mds.25998. Epub 2014 Aug 22.

15.

Recommendations of the Alzheimer's disease-related dementias conference.

Montine TJ, Koroshetz WJ, Babcock D, Dickson DW, Galpern WR, Glymour MM, Greenberg SM, Hutton ML, Knopman DS, Kuzmichev AN, Manly JJ, Marder KS, Miller BL, Phelps CH, Seeley WW, Sieber BA, Silverberg NB, Sutherland M, Torborg CL, Waddy SP, Zlokovic BV, Corriveau RA; ADRD 2013 Conference Organizing Committee.

Neurology. 2014 Aug 26;83(9):851-60. doi: 10.1212/WNL.0000000000000733. Epub 2014 Jul 30. Review.

16.

Hippocampal laminar distribution of tau relates to Alzheimer's disease and age of onset.

Seifan A, Marder KS, Mez J, Noble JM, Cortes EP, Vonsattel JP, Honig LS.

J Alzheimers Dis. 2015;43(1):315-24. doi: 10.3233/JAD-140279.

17.

Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation.

Sharp ME, Marder KS, Côté L, Clark LN, Nichols WC, Vonsattel JP, Alcalay RN.

Mov Disord. 2014 Apr;29(4):566-8. doi: 10.1002/mds.25792. Epub 2013 Dec 27.

18.

Learning fast accurate movements requires intact frontostriatal circuits.

Shabbott B, Ravindran R, Schumacher JW, Wasserman PB, Marder KS, Mazzoni P.

Front Hum Neurosci. 2013 Nov 13;7:752. doi: 10.3389/fnhum.2013.00752. eCollection 2013.

19.

Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.

Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H, Raymond D, Roos E, Orbe-Reilly M, Gurevich T, Bar Shira A, Gana Weisz M, Yasinovsky K, Zalis M, Thaler A, Deik A, Barrett MJ, Cabassa J, Groves M, Hunt AL, Lubarr N, San Luciano M, Miravite J, Palmese C, Sachdev R, Sarva H, Severt L, Shanker V, Swan MC, Soto-Valencia J, Johannes B, Ortega R, Fahn S, Cote L, Waters C, Mazzoni P, Ford B, Louis E, Levy O, Rosado L, Ruiz D, Dorovski T, Pauciulo M, Nichols W, Orr-Urtreger A, Ozelius L, Clark L, Giladi N, Bressman S, Marder KS.

Mov Disord. 2013 Dec;28(14):1966-71. doi: 10.1002/mds.25647. Epub 2013 Oct 15.

20.

Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.

Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS.

JAMA Neurol. 2014 Jan;71(1):62-7. doi: 10.1001/jamaneurol.2013.4498.

21.

Knowledge of and interest in genetic results among Parkinson disease patients and caregivers.

Sakanaka K, Waters CH, Levy OA, Louis ED, Chung WK, Marder KS, Alcalay RN.

J Genet Couns. 2014 Feb;23(1):114-20. doi: 10.1007/s10897-013-9618-y. Epub 2013 Jun 9.

22.

RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk.

MacLeod DA, Rhinn H, Kuwahara T, Zolin A, Di Paolo G, McCabe BD, Marder KS, Honig LS, Clark LN, Small SA, Abeliovich A.

Neuron. 2013 Feb 6;77(3):425-39. doi: 10.1016/j.neuron.2012.11.033. Erratum in: Neuron. 2013 Mar 6;77(5):994. MacCabe, Brian D [corrected to McCabe, Brian D].

23.

Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.

van Nuenen BF, Helmich RC, Ferraye M, Thaler A, Hendler T, Orr-Urtreger A, Mirelman A, Bressman S, Marder KS, Giladi N, van de Warrenburg BP, Bloem BR, Toni I; LRRK2 Ashkenazi Jewish Consortium.

Brain. 2012 Dec;135(Pt 12):3687-98. doi: 10.1093/brain/aws288.

PMID:
23250886
24.

Creation of an open-access, mutation-defined fibroblast resource for neurological disease research.

Wray S, Self M; NINDS Parkinson's Disease iPSC Consortium; NINDS Huntington's Disease iPSC Consortium; NINDS ALS iPSC Consortium, Lewis PA, Taanman JW, Ryan NS, Mahoney CJ, Liang Y, Devine MJ, Sheerin UM, Houlden H, Morris HR, Healy D, Marti-Masso JF, Preza E, Barker S, Sutherland M, Corriveau RA, D'Andrea M, Schapira AH, Uitti RJ, Guttman M, Opala G, Jasinska-Myga B, Puschmann A, Nilsson C, Espay AJ, Slawek J, Gutmann L, Boeve BF, Boylan K, Stoessl AJ, Ross OA, Maragakis NJ, Van Gerpen J, Gerstenhaber M, Gwinn K, Dawson TM, Isacson O, Marder KS, Clark LN, Przedborski SE, Finkbeiner S, Rothstein JD, Wszolek ZK, Rossor MN, Hardy J.

PLoS One. 2012;7(8):e43099. doi: 10.1371/journal.pone.0043099. Epub 2012 Aug 27.

25.

Lack of association between cancer history and PARKIN genotype: a family based study in PARKIN/Parkinson's families.

Alcalay RN, Clark LN, Marder KS, Bradley WE.

Genes Chromosomes Cancer. 2012 Dec;51(12):1109-13. doi: 10.1002/gcc.21995. Epub 2012 Aug 24.

26.

The association between Mediterranean diet adherence and Parkinson's disease.

Alcalay RN, Gu Y, Mejia-Santana H, Cote L, Marder KS, Scarmeas N.

Mov Disord. 2012 May;27(6):771-4. doi: 10.1002/mds.24918. Epub 2012 Feb 7.

27.

Clinical and pathological characteristics of LRRK2 G2019S patients with PD.

Poulopoulos M, Cortes E, Vonsattel JP, Fahn S, Waters C, Cote LJ, Moskowitz C, Honig LS, Clark LN, Marder KS, Alcalay RN.

J Mol Neurosci. 2012 May;47(1):139-43. doi: 10.1007/s12031-011-9696-y. Epub 2011 Dec 23.

28.

Coordination of fingertip forces during precision grip in premanifest Huntington's disease.

Rao AK, Gordon AM, Marder KS.

Mov Disord. 2011 Apr;26(5):862-9. doi: 10.1002/mds.23606. Epub 2011 Mar 10.

29.

Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.

Caccappolo E, Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Cote LJ, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Siderowf AD, Ross BM, Verbitsky M, Kisselev S, Ottman R, Clark LN, Marder KS.

J Int Neuropsychol Soc. 2011 Jan;17(1):91-100. doi: 10.1017/S1355617710001190. Epub 2010 Nov 24.

30.

Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study.

Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Neils GD, Verbitsky M, Kisselev S, Caccappolo E, Ottman R, Clark LN.

Arch Neurol. 2010 Jun;67(6):731-8. doi: 10.1001/archneurol.2010.95.

31.

Comorbidities of obsessive and compulsive symptoms in Huntington's disease.

Anderson KE, Gehl CR, Marder KS, Beglinger LJ, Paulsen JS; Huntington's Study Group.

J Nerv Ment Dis. 2010 May;198(5):334-8. doi: 10.1097/NMD.0b013e3181da852a.

32.

Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.

Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS, Caccappolo E.

J Clin Exp Neuropsychol. 2010 Aug;32(7):775-9. doi: 10.1080/13803390903521018. Epub 2010 Feb 24.

33.

Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.

Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS.

Arch Neurol. 2009 Dec;66(12):1517-22. doi: 10.1001/archneurol.2009.267.

34.

Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort.

Uc EY, McDermott MP, Marder KS, Anderson SW, Litvan I, Como PG, Auinger P, Chou KL, Growdon JC; Parkinson Study Group DATATOP Investigators.

Neurology. 2009 Nov 3;73(18):1469-77. doi: 10.1212/WNL.0b013e3181bf992f.

35.

Clinical assessment of mobility and balance impairments in pre-symptomatic Huntington's disease.

Rao AK, Louis ED, Marder KS.

Gait Posture. 2009 Oct;30(3):391-3. doi: 10.1016/j.gaitpost.2009.07.006. Epub 2009 Jul 31.

36.

Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations.

Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Marder KS, Foroud T, Nichols WC; Parkinson Study Group-PROGENI Investigators.

Neurology. 2009 Jul 28;73(4):279-86. doi: 10.1212/WNL.0b013e3181af7a33.

37.

Genetic aspects of Alzheimer disease.

Williamson J, Goldman J, Marder KS.

Neurologist. 2009 Mar;15(2):80-6. doi: 10.1097/NRL.0b013e318187e76b. Review.

38.

Clinical measurement of mobility and balance impairments in Huntington's disease: validity and responsiveness.

Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS.

Gait Posture. 2009 Apr;29(3):433-6. doi: 10.1016/j.gaitpost.2008.11.002. Epub 2008 Dec 25.

PMID:
19111470
39.

Clinical correlates of depressive symptoms in familial Parkinson's disease.

Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T; Parkinson's Study Group-PROGENI Investigators.

Mov Disord. 2008 Nov 15;23(15):2216-23. doi: 10.1002/mds.22285.

40.

Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease.

Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS.

Mov Disord. 2008 Jun 15;23(8):1100-7. doi: 10.1002/mds.21987.

PMID:
18412252
41.

A tale of two etiologies: loss and recovery of olfactory function.

Albers MW, Marder KS.

Ann Neurol. 2008 Feb;63(2):132-4. doi: 10.1002/ana.21330. No abstract available.

PMID:
18306414
42.

Pooled analysis of tobacco use and risk of Parkinson disease.

Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, Ross GW, Strickland D, Van Den Eeden SK, Gorell J.

Arch Neurol. 2007 Jul;64(7):990-7.

PMID:
17620489
43.

Impairment of nonverbal recognition in Alzheimer disease: a PET O-15 study.

Anderson KE, Brickman AM, Flynn J, Scarmeas N, Van Heertum R, Sackeim H, Marder KS, Bell K, Moeller JR, Stern Y.

Neurology. 2007 Jul 3;69(1):32-41. Epub 2007 May 30.

PMID:
17538034
44.

Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study.

Elbaz A, Nelson LM, Payami H, Ioannidis JP, Fiske BK, Annesi G, Carmine Belin A, Factor SA, Ferrarese C, Hadjigeorgiou GM, Higgins DS, Kawakami H, Krüger R, Marder KS, Mayeux RP, Mellick GD, Nutt JG, Ritz B, Samii A, Tanner CM, Van Broeckhoven C, Van Den Eeden SK, Wirdefeldt K, Zabetian CP, Dehem M, Montimurro JS, Southwick A, Myers RM, Trikalinos TA.

Lancet Neurol. 2006 Nov;5(11):917-23.

45.

Dementia in Parkinson's disease.

Rippon GA, Marder KS.

Adv Neurol. 2005;96:95-113. Review.

PMID:
16383215
46.

A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington's disease.

Chatterjee A, Anderson KE, Moskowitz CB, Hauser WA, Marder KS.

J Neuropsychiatry Clin Neurosci. 2005 Summer;17(3):378-83.

PMID:
16179661
47.

Reliability of spatiotemporal gait outcome measures in Huntington's disease.

Rao AK, Quinn L, Marder KS.

Mov Disord. 2005 Aug;20(8):1033-7.

PMID:
15838854
48.

Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis.

Scarmeas N, Zarahn E, Anderson KE, Habeck CG, Hilton J, Flynn J, Marder KS, Bell KL, Sackeim HA, Van Heertum RL, Moeller JR, Stern Y.

Arch Neurol. 2003 Mar;60(3):359-65.

49.

Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. 1994.

Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, Sima AA, Keohane C, Nygaard TG, Fahn S, Mayeux R, Rowland LP, Wilhelmsen KC.

Neurology. 2001 Nov;57(10 Suppl 3):S39-45. No abstract available.

PMID:
11775599
50.

An overview of psychiatric symptoms in Huntington's disease.

Anderson KE, Marder KS.

Curr Psychiatry Rep. 2001 Oct;3(5):379-88. Review.

PMID:
11559474

Supplemental Content

Loading ...
Support Center